<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541225</url>
  </required_header>
  <id_info>
    <org_study_id>NUV-422-02</org_study_id>
    <nct_id>NCT04541225</nct_id>
  </id_info>
  <brief_title>Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors</brief_title>
  <official_title>Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuvation Bio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nuvation Bio Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NUV-422-02 is a first-in-human, open-label, Phase 1/2 dose escalation and multiple expansion&#xD;
      cohort study designed to evaluate the safety and efficacy of NUV-422. The study population is&#xD;
      comprised of adults with recurrent or refractory high-grade gliomas (HGGs), metastatic breast&#xD;
      cancer (mBC), with and without brain metastases, and recurrent or refractory metastatic&#xD;
      castration-resistant prostate cancer (mCRPC). All patients will self-administer NUV-422&#xD;
      orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or&#xD;
      termination of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 Dose Escalation</measure>
    <time_frame>During the DLT period (28 days)</time_frame>
    <description>Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion Cohort 1</measure>
    <time_frame>Every 8 weeks through study treatment, an average of 6 months</time_frame>
    <description>Objective response rate (ORR) and Duration of Response (DOR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion Cohort 2</measure>
    <time_frame>Intraoperatively after 21 days of study treatment</time_frame>
    <description>Evaluation of NUV-422 concentration in plasma, including peak plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion Cohort 2</measure>
    <time_frame>Intraoperatively after 21 days of study treatment</time_frame>
    <description>Evaluation of NUV-422 half-life in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion Cohort 2</measure>
    <time_frame>Intraoperatively after 21 days of study treatment</time_frame>
    <description>Evaluation of NUV-422 concentration in brain tumor tissue</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion Cohort 2</measure>
    <time_frame>Intraoperatively after 21 days of study treatment</time_frame>
    <description>Evaluation of NUV-422 effects on brain tumor cell proliferation ratio pre- and post-treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion Cohort 3</measure>
    <time_frame>Every 8 weeks through study treatment, an average of 6 months</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion Cohort 3</measure>
    <time_frame>Every 8 weeks through study treatment, an average of 6 months</time_frame>
    <description>DOR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion Cohort 4</measure>
    <time_frame>Every 8 weeks through study treatment, an average of 6 months</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion Cohort 4</measure>
    <time_frame>Every 8 weeks through study treatment, an average of 6 months</time_frame>
    <description>DOR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion Cohort 4</measure>
    <time_frame>Every 4 weeks through study treatment, an average of 6 months</time_frame>
    <description>Decrease in the prostate-specific antigen (PSA) pre- and post-treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion Cohort 5</measure>
    <time_frame>Every 8 weeks through study treatment, an average of 6 months</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Dose Expansion Cohort 5</measure>
    <time_frame>Every 8 weeks through study treatment, an average of 6 months</time_frame>
    <description>DOR</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Glioma</condition>
  <condition>Glioma, Malignant</condition>
  <condition>Glioma, Mixed</condition>
  <condition>Glial Cell Tumors</condition>
  <condition>Breast Cancer</condition>
  <condition>Breast Carcinoma</condition>
  <condition>Cancer of Breast</condition>
  <condition>Cancer of the Breast</condition>
  <condition>Breast Tumor</condition>
  <condition>Malignant Tumor of Breast</condition>
  <condition>Prostate Cancer</condition>
  <condition>Prostatic Cancer</condition>
  <condition>Cancer of Prostate</condition>
  <condition>Cancer of the Prostate</condition>
  <condition>Prostate Neoplasm</condition>
  <arm_group>
    <arm_group_label>Phase 1 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NUV-422 administered at escalating dose levels until the maximum tolerated dose (MTD) is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NUV-422 administered at the recommended Phase 2 dose (RP2D).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NUV-422</intervention_name>
    <description>NUV-422</description>
    <arm_group_label>Phase 1 Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
        For All Phases and Cohorts:&#xD;
&#xD;
          1. Recovered from toxicity to prior anti-cancer therapy&#xD;
&#xD;
          2. Adequate bone marrow and organ function&#xD;
&#xD;
          3. Appropriate candidate for NUV-422 monotherapy&#xD;
&#xD;
          4. Life expectancy of &gt; 3 months&#xD;
&#xD;
        Cohort-Specific Inclusion Criteria: In addition to the inclusion criteria listed above, the&#xD;
        following criteria apply based on enrollment into specific cohorts.&#xD;
&#xD;
        Phase 1 (High-Grade Glioma):&#xD;
&#xD;
          1. Histologically confirmed diagnosis of high-grade glioma&#xD;
&#xD;
          2. Evidence of recurrence after treatment (ie, surgery, radiation, or temozolomide) or&#xD;
             refractory (or intolerant) to treatment&#xD;
&#xD;
          3. Measurable or non-measurable disease&#xD;
&#xD;
          4. Karnofsky Performance Status (KPS) score ≥ 60&#xD;
&#xD;
        Phase 1 (HR+HER2- Metastatic Breast Cancer):&#xD;
&#xD;
          1. Men and women who are not suitable for surgical resection or radiotherapy for the&#xD;
             purpose of cure&#xD;
&#xD;
          2. Diagnosis of locally advanced or HR+ HER2 metastatic breast cancer&#xD;
&#xD;
          3. Evidence of progression as determined by the Investigator per standard criteria&#xD;
&#xD;
          4. Patients must have endocrine-resistant disease.&#xD;
&#xD;
          5. Have no known active or symptomatic central nervous system (CNS) disease&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2&#xD;
&#xD;
        Phase 1 (Metastatic Castration-Resistant Prostate Cancer):&#xD;
&#xD;
          1. Diagnosis of metastatic castration-resistant prostate cancer with disease progression&#xD;
             despite castrate levels of testosterone&#xD;
&#xD;
          2. Have radiographic or biochemical evidence of progression as determined by the&#xD;
             Investigator per standard criteria&#xD;
&#xD;
          3. Have no known active or symptomatic CNS disease&#xD;
&#xD;
          4. Received prior therapy with anti-androgen(s) and taxane-based chemotherapy for&#xD;
             castration-resistant disease&#xD;
&#xD;
          5. ECOG PS ≤ 2&#xD;
&#xD;
        Phase 2 Expansion Cohort 1 (Glioblastoma):&#xD;
&#xD;
          1. Histologically confirmed diagnosis of glioblastoma&#xD;
&#xD;
          2. Received prior therapy with radiation or radiation plus temozolomide&#xD;
&#xD;
          3. Radiographic evidence of progression and measurable disease as determined by the&#xD;
             Investigator per standard criteria&#xD;
&#xD;
          4. KPS score ≥ 70&#xD;
&#xD;
        Phase 2 Expansion Cohort 2 (Glioblastoma):&#xD;
&#xD;
          1. Histologically confirmed diagnosis of glioblastoma&#xD;
&#xD;
          2. Received prior therapy with radiation or radiation plus temozolomide&#xD;
&#xD;
          3. Radiographic evidence of progression and measurable disease as determined by the&#xD;
             Investigator per standard criteria&#xD;
&#xD;
          4. KPS score ≥ 70&#xD;
&#xD;
          5. Eligible for surgical resection&#xD;
&#xD;
        Phase 2 Expansion Cohort 3 (HR+HER2- Metastatic Breast Cancer):&#xD;
&#xD;
          1. Men and women who are not suitable for surgical resection or radiotherapy for the&#xD;
             purpose of cure&#xD;
&#xD;
          2. Diagnosis of locally advanced or HR+HER2- metastatic breast cancer&#xD;
&#xD;
          3. Evidence of progression and measurable disease as determined by the Investigator per&#xD;
             standard criteria&#xD;
&#xD;
          4. Have no known active or symptomatic CNS disease&#xD;
&#xD;
          5. ECOG PS ≤ 2&#xD;
&#xD;
        Phase 2 Expansion Cohort 4 (Metastatic Castration-Resistant Prostate Cancer):&#xD;
&#xD;
          1. Diagnosis of metastatic castration-resistant prostate cancer with disease progression&#xD;
             despite castrate levels of testosterone&#xD;
&#xD;
          2. Have radiographic or biochemical evidence of progression and measurable disease as&#xD;
             determined by the Investigator per standard criteria&#xD;
&#xD;
          3. Have no known active or symptomatic CNS disease&#xD;
&#xD;
          4. Received prior therapy with anti-androgen(s) and taxane-based chemotherapy for&#xD;
             castration-resistant disease&#xD;
&#xD;
          5. ECOG PS ≤ 2&#xD;
&#xD;
        Phase 2 Expansion Cohort 5 (HR+HER2- Metastatic Breast Cancer with brain metastases)&#xD;
&#xD;
          1. Men and women who are not suitable for surgical resection or radiotherapy for the&#xD;
             purpose of cure&#xD;
&#xD;
          2. Diagnosis of HR+HER2- metastatic breast cancer with brain lesion(s)&#xD;
&#xD;
          3. Evidence of progression and measurable disease as determined by the Investigator per&#xD;
             standard criteria&#xD;
&#xD;
          4. ECOG PS ≤ 2&#xD;
&#xD;
        Key Exclusion Criteria for All Phases and Cohorts:&#xD;
&#xD;
          1. Have received chemotherapy, hormonal therapy (with the exception of ongoing LHRH&#xD;
             analogs in male patients and premenopausal women), radiation, or biological&#xD;
             anti-cancer therapy within 14 days prior to the first dose of NUV-422&#xD;
&#xD;
          2. Has a history of or current use of bevacizumab (glioma and brain metastases only)&#xD;
&#xD;
          3. Received treatment with an investigational agent for any indication within 14 days for&#xD;
             non-myelosuppressive agent or 21 days (or &lt; 5 half-lives) for myelosuppressive agent&#xD;
             prior to the first dose of NUV-422&#xD;
&#xD;
          4. Requires systemic corticosteroid therapy &gt; 4 mg/day (&gt; 2 mg/day for Expansion Cohort&#xD;
             2) of dexamethasone or equivalent or increasing doses of systemic corticosteroids&#xD;
             during the 7 days prior to enrollment&#xD;
&#xD;
          5. Requires anti-seizure medications that are known to be strong inducers of CYP3A4/5&#xD;
             enzymes (carbamazepine, phenytoin) or has a recent history of uncontrolled or&#xD;
             intermittent seizures&#xD;
&#xD;
          6. Females who are pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials at Nuvation Bio</last_name>
    <phone>332-208-6102</phone>
    <email>ClinicalTrials@nuvationbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Y Wen, MD</last_name>
      <phone>617-632-2166</phone>
    </contact>
    <contact_backup>
      <last_name>Rachel Fox</last_name>
      <phone>617-632-6668</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kaley, MD</last_name>
      <phone>212-639-5122</phone>
    </contact>
    <contact_backup>
      <last_name>Christine Jarjies</last_name>
      <phone>646-907-2567</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley McClain</last_name>
      <phone>980-441-1021</phone>
      <email>AMcClain@carolinabiooncology.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Rodon, MD, PhD</last_name>
      <phone>713-563-1930</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Colman, MD</last_name>
      <phone>801-585-0255</phone>
      <email>Howard.Colman@hci.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sara Woltz</last_name>
      <phone>801-585-0431</phone>
      <email>Sara.Woltz@hci.utah.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Phase 2</keyword>
  <keyword>malignant glioma</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>metastatic castration-resistant prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

